ClinicalTrials.gg
CompletedNCT06601192Updated Jul 28, 2025

A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults

A Phase 1 interventional study of zelicapavir (therapeutic dose) and zelicapavir (supratherapeutic dose) in RSV Infection and QTc Interval, sponsored by Enanta Pharmaceuticals, Inc. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-28.

Sponsored by Enanta Pharmaceuticals, Inc · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections — 1 open to participants now, 1 under way, none of them phase 3. EDP-938 · Respiratory Syncytial Virus Infections.

Enrollment
6th of 10
72 · median 81
Started
2024
the only one that year
Phase 1
6 of 10
none open now
Registered
9th of 10
by date
Lead sponsor
10 of 10
Enanta Pharmaceuticals, Inc

Among the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections, this one is the 6th largest by enrollment, is the only one that started in 2024, is one of 6 in phase 1, and was the 9th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About EDP-938

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections, or all of them as a file.
02

Study summary

The purpose of the study is to assess the effect of a therapeutic and supratherapeutic dose of zelicapavir on the corrected cardiac QT interval relative to a placebo and positive control in healthy participants.

03

Conditions studied

  • RSV Infection
  • QTc Interval
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An document signed and dated by the subject.
  • Male or female individuals who are 18 to 65 years of age, inclusive
  • Screening (BMI) of 18 to 30 kg/m2 with a minimum body weight of 50 kg
  • Heterosexually active male participants and their female partners of must agree to use 2 effective methods for the duration of the study and for 90 days after the last dose of study intervention.
  • Females of childbearing potential must agree to use 2 effective birth control methods for the duration of the study and for 30 days after the last dose of study intervention.

Exclusion criteria

Exclusion Criteria:

  • evidence or history of illness or disease
  • Clinically relevant risk factors for cardiovascular abnormalities
  • Pregnant or nursing females
  • History of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection
  • Infection with , , , or SARS CoV 2
  • Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy)
  • Before the first dose of study intervention, participant has received any vaccine, an agent or biological product within 28 days or 5 times the terminal half-life (t½), whichever is longer
  • A positive urine drug screen at Screening or Day -1
  • Current tobacco smokers or use of tobacco within 3 months prior to Screening
  • History of regular alcohol consumption
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    zelicapavir Dose 1 (therapeutic dose)

    All participants will receive 4 study interventions. The study interventions will be administered during separate treatment periods starting on Days 1, 9, 17, and 25.

    Drug: zelicapavir (therapeutic dose)

  • Experimental
    zelicapavir Dose 2 (supratherapeutic dose)

    All participants will receive 4 study interventions. The study interventions will be administered during separate treatment periods starting on Days 1, 9, 17, and 25.

    Drug: zelicapavir (supratherapeutic dose)

  • Placebo comparator
    placebo

    All participants will receive 4 study interventions. The study interventions will be administered during separate treatment periods starting on Days 1, 9, 17, and 25.

    Drug: Placebo

  • Experimental
    moxifloxacin

    All participants will receive 4 study interventions. The study interventions will be administered during separate treatment periods starting on Days 1, 9, 17, and 25.

    Drug: moxifloxacin

Interventions

  • Subjects will receive zelicapavir (TD) once per treatment period.

    Also known as: EDP-938

  • Subjects will receive zelicapavir (SD) once per treatment period.

    Also known as: EDP-938

  • DrugPlacebo

    Subjects will receive zelicapavir matching placebo once per treatment period.

  • Subjects will receive moxifloxin once per treatment period.

06

What researchers measure

Primary outcomes

  1. Time-matched, placebo-corrected change-from-baseline QTc based on the Fridericia correction QTcF (ΔΔQTcF) after TD and SD of Zelicapavir

    Time frame: Up to 24 hours post dose

Secondary outcomes

  1. Time-matched, placebo-corrected, change-from-baseline non-QT intervals after TD and SD of Zelicapavir

    Time frame: Up to 24 hours post dose

  2. Time-matched, placebo-corrected, change-from-baseline HR after TD and SD of Zelicapavir

    Time frame: Up to 24 hours post dose

  3. Concentration-QTc analysis based on the relationship between plasma concentrations of zelicapavir and ΔΔQTcF after a TD and SD of zelicapavir

    Time frame: Up to 96 hours post dose

  4. Cmax of zelicapavir

    Time frame: Up to 96 hours post dose

  5. Tmax of zelicapavir

    Time frame: Up to 96 hours post dose

  6. t1/2 of zelicapavir

    Time frame: Up to 96 hours post dose

  7. Vd/F of zelicapavir

    Time frame: Up to 96 hours post dose

  8. CL/F of zelicapavir

    Time frame: Up to 96 hours post dose

  9. ΔΔQTcF after moxifloxacin dosing

    Time frame: Up to 24 hours post dose

  10. Safety measured by adverse events

    Time frame: Up to Day 33

07

Study locations

2 sites
  • ICON
    Lenexa, Kansas 66219, United States
  • ICON Early Phase, LLC
    San Antonio, Texas 78290, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Feb 2025, 6 months.

Of 44 industry-sponsored phase 1 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 6 months is close to that.

Counting every sponsor, half of 57 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2024
First posted
Sep 19, 2024
StartActual
Jul 15, 2024
Primary completionActual
Feb 2, 2025
CompletionActual
Feb 25, 2025
Last update
Jul 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06601192
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Jul 15, 2024
Primary completion
Feb 2, 2025
Completion
Feb 25, 2025
Last update
Jul 28, 2025

Study contacts

Enanta Pharmaceuticals, Inc
study director · Enanta Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: EDP-938 · Moxifloxacin

Start the discussion